SCHEMBL24218596

CC(C)[C@@H]1NC(=O)[C@H](Cc2ccccc2)NC(=O)CSC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CO)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)N(C)C(=O)[C@H](Cc2ccc(-c3ccccc3)cc2)NC(=O)[C@H](C)N(C)C(=O)[C@H](Cc2ccc(-c3ccccc3)cc2)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC1=O

nearest known ligand 0.55

Predicted protein targets (top 9)

	gene	UniProt	supporting neighbours	confidence
▸	KLKB1	P03952	8/20	0.55

▸	CD274	Q9NZQ7	2/20	0.52

▸	PDCD1	Q15116	1/20	0.52

▸	KLK5	Q9Y337	3/20	0.50

▸	ALB	P02768	1/20	0.48

▸	CIB1	Q99828	2/20	0.48

▸	PLAU	P00749	2/20	0.47

▸	CTSG	P08311	1/20	0.47

▸	SLC6A3	Q01959	1/20	0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL24218688	0.98	KLKB1 (0.53)	KLKB1CD274PDCD1KLK5ALB
SCHEMBL24218642	0.98	KLKB1 (0.53)	KLKB1CD274PDCD1KLK5ALB
SCHEMBL24218603	0.98	KLKB1 (0.53)	KLKB1CD274PDCD1KLK5ALB
SCHEMBL24218687	0.98	KLKB1 (0.53)	KLKB1CD274PDCD1KLK5ALB
SCHEMBL24218590	0.97	KLKB1 (0.57)	KLKB1CD274PDCD1KLK5ALB
SCHEMBL24218656	0.97	KLKB1 (0.56)	KLKB1CD274PDCD1KLK5ALB
SCHEMBL24218602	0.96	CD274 (0.53)	KLKB1CD274PDCD1KLK5ALB
SCHEMBL24218597	0.96	CD274 (0.53)	KLKB1CD274PDCD1KLK5ALB
SCHEMBL24218685	0.96	KLKB1 (0.55)	KLKB1CD274PDCD1KLK5CIB1
SCHEMBL24218638	0.95	KLKB1 (0.56)	KLKB1CD274PDCD1KLK5ALB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-20220024981-A1	CYCLIC PEPTIDES AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS	NOVARTIS AG (CH)	2022-01-27	—	—	US	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20220024981-A1	CYCLIC PEPTIDES AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS	PCSK9, PCSK7, PCSK6	KLKB1 67/4885CD274 3229/4885PDCD1 1778/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.